search
Back to results

Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253

Primary Purpose

Rectal Carcinoma, Sigmoid Colon Carcinoma

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
lymph nodes dissection at 253 station assisted by ICG
Sponsored by
Nanfang Hospital, Southern Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Rectal Carcinoma focused on measuring ICG, 253 lymph nodes, rectal carcinoma, sigmoid colon carcinoma

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

(1)18-80 years of age (2)American Society of Anesthesiologists (ASA) class 1-3 (3)single rectal or sigmoid colon carcinoma confirmed pathologically by endoscopic biopsy (4)planned laparoscopic radical resection (5)Written informed consent

Exclusion Criteria:

  1. previous abdominal tumor surgery
  2. women who are pregnant or breast feeding
  3. emergency patients with obstruction or perforation
  4. T4b cancer evaluated by CT or MRI or endoscopic ultrasonography
  5. pelvic or distant metastasis
  6. T1 cancer planned local excision
  7. allergic constitution patients

Sites / Locations

  • Nanfang Hospital, Southern Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

ICG group

CLgroup

Arm Description

Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.

Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.

Outcomes

Primary Outcome Measures

number of harvested station 253 lymph nodes
number of harvested station 253 lymph nodes,number of positive station 253 lymph nodes,rate of positive station 253 lymph nodes

Secondary Outcome Measures

number of harvested station 251 lymph nodes
number of harvested station 251 lymph nodes, number of positive station 251 lymph nodes, rate of positive station 251 lymph nodes,
number of harvested station 252 lymph nodes
number of harvested station 252 lymph nodes, number of positive station 252 lymph nodes , rate of positive station 252 lymph nodes
number of total lymph nodes harvested
number of total lymph nodes harvested, number of total positive lymph nodes ,rate of total positive lymph nodes

Full Information

First Posted
April 12, 2021
Last Updated
April 16, 2021
Sponsor
Nanfang Hospital, Southern Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT04848311
Brief Title
Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253
Official Title
Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253 of Rectal and Sigmoid Colon Carcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 1, 2021 (Anticipated)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
May 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nanfang Hospital, Southern Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective randomized controlled study. investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group to compare the differences of lymph nodes dissection in station 253 between the two groups.
Detailed Description
ICG is a registered and FDA-approved non-specific fluorescent probe for optical imaging in clinical settings. The properties of ICG ,which is a water-soluble amphiphilic molecule with a molecular weight of 775 Dalton and a hydrodynamic diameter of 1.2nm ,render it an excellent lymphatic contrast agents if injected into the lymphatic system. ICG near-infrared(NIR) fluorescent imaging has achieved satisfactory results in the localization of sentinel lymph nodes in patients with breast cancer,non-small cell lung cancer,and gastric cancer. Liang et al have suggested that 253 lymph nodes dissection in rectal cancer is technically demanding ,and that learning curve for laparoscopic 253 lymph nodes dissection requires minimally 20 procedures. Currently,it was still controversial about 253 lymph nodes dissection in rectal cancer surgery. However, lymph node involvement is a major prognostic factor for survival after rectal cancer surgery. Therefore, it is necessary to harvest more station 253 nodes for the better long-term survival and the more precise staging. In this study, investigators will randomly assign patients to the indocanine green (ICG) group and control (CL)group. Number of harvested station 253 lymph nodes, number of positive station 253 lymph nodes, will be evaluated and compared. Investigators will also evaluate patients, operative time, blood loss, post-operative hospital stay and complications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Carcinoma, Sigmoid Colon Carcinoma
Keywords
ICG, 253 lymph nodes, rectal carcinoma, sigmoid colon carcinoma

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
66 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ICG group
Arm Type
Experimental
Arm Description
Patients in the ICG group will undergo endoscopic injection of ICG 4 hours before surgery. The ICG powder will be dissolved in 2.5mg/ml of sterile water. ICG will be injected along the submucosa at 4 points around the primary tumor,for a total volume of 10ml.
Arm Title
CLgroup
Arm Type
No Intervention
Arm Description
Patients in the CL group will undergo routine laparoscopic lymph nodes dissection instead of using any tracer.
Intervention Type
Procedure
Intervention Name(s)
lymph nodes dissection at 253 station assisted by ICG
Intervention Description
In ICG group :All patients will be subjected to laparoscopic radical resection with station 253 lymph nodes dissection by fluorescence laparoscopic.
Primary Outcome Measure Information:
Title
number of harvested station 253 lymph nodes
Description
number of harvested station 253 lymph nodes,number of positive station 253 lymph nodes,rate of positive station 253 lymph nodes
Time Frame
one week after operation
Secondary Outcome Measure Information:
Title
number of harvested station 251 lymph nodes
Description
number of harvested station 251 lymph nodes, number of positive station 251 lymph nodes, rate of positive station 251 lymph nodes,
Time Frame
one week after operation
Title
number of harvested station 252 lymph nodes
Description
number of harvested station 252 lymph nodes, number of positive station 252 lymph nodes , rate of positive station 252 lymph nodes
Time Frame
one week after operation
Title
number of total lymph nodes harvested
Description
number of total lymph nodes harvested, number of total positive lymph nodes ,rate of total positive lymph nodes
Time Frame
one week after operation
Other Pre-specified Outcome Measures:
Title
operative time
Time Frame
intraoperative
Title
post-operative data
Description
blood loss
Time Frame
one hour after operation
Title
post-operative hospital stay
Description
post-operative hospital stay
Time Frame
two weeks after operation
Title
complications
Description
post-operative data
Time Frame
two weeks after operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: (1)18-80 years of age (2)American Society of Anesthesiologists (ASA) class 1-3 (3)single rectal or sigmoid colon carcinoma confirmed pathologically by endoscopic biopsy (4)planned laparoscopic radical resection (5)Written informed consent Exclusion Criteria: previous abdominal tumor surgery women who are pregnant or breast feeding emergency patients with obstruction or perforation T4b cancer evaluated by CT or MRI or endoscopic ultrasonography pelvic or distant metastasis T1 cancer planned local excision allergic constitution patients
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jun Yan, M.D,Ph.D
Phone
13825066546
Email
yanjunfudan@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jun Yan, M.D,Ph.D
Organizational Affiliation
Nanfang Hospital, Southern Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nanfang Hospital, Southern Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jun Yan, M.D.,Ph.D
Phone
086-13825066546
Email
yanjunfudan@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253

We'll reach out to this number within 24 hrs